1. Home
  2. KOS vs MESO Comparison

KOS vs MESO Comparison

Compare KOS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$2.44

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.50

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
MESO
Founded
2003
2004
Country
United States
Australia
Employees
N/A
81
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
KOS
MESO
Price
$2.44
$15.50
Analyst Decision
Hold
Strong Buy
Analyst Count
6
1
Target Price
$1.91
N/A
AVG Volume (30 Days)
9.9M
123.6K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,288,352,000.00
N/A
Revenue This Year
$27.11
$629.74
Revenue Next Year
N/A
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$10.17
52 Week High
$3.34
$21.50

Technical Indicators

Market Signals
Indicator
KOS
MESO
Relative Strength Index (RSI) 36.62 59.17
Support Level $2.33 $13.71
Resistance Level $3.09 $16.11
Average True Range (ATR) 0.16 0.49
MACD -0.06 0.09
Stochastic Oscillator 13.64 84.89

Price Performance

Historical Comparison
KOS
MESO

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: